Consolidated and Standalone Audited Financial Results of the Company for the quarter and year ended March 31, 2026, is attached.
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.9 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Agarwal's Health Care Limited delivered strong FY2026 results with Total Income surging 20.9% YoY to ₹2,125 Crores. Revenue from Operations grew 21.6% to ₹2,080 Crores, crossing the ₹2,000 crore milestone for the first time. EBITDA expanded 22.2% to ₹614 Crores with margins at 28.9%, while PAT grew 52.4% to ₹168 Crores. The company added 57 new facilities during the year, taking its network to 288 facilities across 10 countries, and performed 323,245 surgeries (up 14.5% YoY). Mature facilities showed particularly strong growth at 35.3%. The Board also approved reallocation of ₹14.88 Crores of unspent IPO proceeds from Issue Related Expenses to General Corporate Purposes. Auditors S.R. Batliboi & Associates LLP issued an unmodified opinion with no going concern or qualification flags.
The company demonstrates robust growth across all metrics with improving profitability. PAT growth of 52.4% significantly outpaces revenue growth, indicating operational leverage. The strong cash generation (operating cash flow of ₹519 Crores) and expansion of the network position the company well for continued growth. Clean audit opinion with no concerns supports financial reliability.